Ruxolitinib ≥98% (by HPLC)

Supplier: ADIPOGEN CORP MS
Warning

Synonyms: (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile, INCB018424, Ruxolitinib

AG-CR1-3624-M005 AG-CR1-3624-M025
102988-810EA 90 USD
102988-810 102988-812
Ruxolitinib ≥98% (by HPLC)
Ruxolitinib

Antineoplastic, anti-inflammatory and immunomodulating agent. Orally bioavailable potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5nM, respectively and is less selective for JAK3 (IC50=322nM). Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro.

Formula: C₁₇H₁₈N₆
MW: 306.4 g/mol
Storage Temperature: Freezer
MDL Number: MFCD12031592
CAS Number: 941678-49-5

Order Now

Specification Test Results

Purity >98% (HPLC)
Appearance/Color White to off-white solid.
Solubility Soluble in DMSO or ethanol. Insoluble in water.

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR